PH12020500542A1 - Dopamine-b-hydroxylase inhibitors - Google Patents

Dopamine-b-hydroxylase inhibitors

Info

Publication number
PH12020500542A1
PH12020500542A1 PH12020500542A PH12020500542A PH12020500542A1 PH 12020500542 A1 PH12020500542 A1 PH 12020500542A1 PH 12020500542 A PH12020500542 A PH 12020500542A PH 12020500542 A PH12020500542 A PH 12020500542A PH 12020500542 A1 PH12020500542 A1 PH 12020500542A1
Authority
PH
Philippines
Prior art keywords
compounds
solvates
dopamine
salts
hydroxylase inhibitors
Prior art date
Application number
PH12020500542A
Other languages
English (en)
Inventor
Laszlo Erno Kiss
Alexander Beliaev
Tino Rossi
Pedro Nuno Leal Palma
Da Silva Patr¡Cio Manuel Vieira Araujo Soares
Rui Pinto
Francisco Cardona
Original Assignee
Bial Portela And Ca S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1720189.8A external-priority patent/GB201720189D0/en
Priority claimed from GBGB1804439.6A external-priority patent/GB201804439D0/en
Application filed by Bial Portela And Ca S A filed Critical Bial Portela And Ca S A
Publication of PH12020500542A1 publication Critical patent/PH12020500542A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12020500542A 2017-12-04 2020-06-02 Dopamine-b-hydroxylase inhibitors PH12020500542A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720189.8A GB201720189D0 (en) 2017-12-04 2017-12-04 Dopamine-B-hydroxylase inhibitors
GBGB1804439.6A GB201804439D0 (en) 2018-03-20 2018-03-20 Dopamin-b-hydroxylase inhibitors
PCT/PT2018/050043 WO2019112457A1 (en) 2017-12-04 2018-11-30 Dopamine-β-hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
PH12020500542A1 true PH12020500542A1 (en) 2021-01-25

Family

ID=65012066

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020500542A PH12020500542A1 (en) 2017-12-04 2020-06-02 Dopamine-b-hydroxylase inhibitors

Country Status (16)

Country Link
US (2) US11434242B2 (https=)
EP (1) EP3720856A1 (https=)
JP (1) JP7167155B2 (https=)
KR (1) KR20200096584A (https=)
CN (1) CN111479812A (https=)
AU (1) AU2018379646A1 (https=)
BR (1) BR112020010216A2 (https=)
CA (1) CA3082337A1 (https=)
CL (1) CL2020001461A1 (https=)
IL (1) IL274550B2 (https=)
MX (1) MX2020005864A (https=)
PH (1) PH12020500542A1 (https=)
RU (1) RU2020121820A (https=)
SG (1) SG11202004231YA (https=)
TW (1) TW201925193A (https=)
WO (1) WO2019112457A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
US20250122171A1 (en) * 2023-09-20 2025-04-17 Deep Apple Therapeutics, Inc. Substituted Amine Compounds, Compositions and Methods of Use
CN120383599A (zh) * 2024-01-29 2025-07-29 上海深势唯思科技有限责任公司 芳基杂环类Kv1.3抑制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
FR2449689A1 (fr) 1979-02-20 1980-09-19 Logeais Labor Jacques Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique
US4628059A (en) 1985-10-31 1986-12-09 Smithklein Beckman Corporation Dopamine-β-hydroxylase inhibitors
WO1995029165A2 (en) 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors
US6482982B1 (en) 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
US7125904B2 (en) 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
WO2008085008A1 (en) 2007-01-11 2008-07-17 Mogam Biotechnology Research Institute T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
JP2010534676A (ja) 2007-07-23 2010-11-11 シノシア・セラピューティクス 心的外傷後ストレス障害の治療
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂

Also Published As

Publication number Publication date
IL274550B2 (en) 2023-06-01
US11434242B2 (en) 2022-09-06
JP7167155B2 (ja) 2022-11-08
WO2019112457A1 (en) 2019-06-13
TW201925193A (zh) 2019-07-01
CN111479812A (zh) 2020-07-31
IL274550A (en) 2020-06-30
MX2020005864A (es) 2020-09-09
US20210171528A1 (en) 2021-06-10
SG11202004231YA (en) 2020-06-29
KR20200096584A (ko) 2020-08-12
BR112020010216A2 (pt) 2020-09-15
JP2021505568A (ja) 2021-02-18
CA3082337A1 (en) 2019-06-13
CL2020001461A1 (es) 2020-10-16
AU2018379646A1 (en) 2020-06-11
US20230138795A1 (en) 2023-05-04
RU2020121820A (ru) 2022-01-10
EP3720856A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
PH12021551134A1 (en) Oxysterols and methods of use thereof
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
NZ759295A (en) 5-5 fused rings as c5a inhibitors
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
ZA201607489B (en) Combination comprising a glucocorticoid and edo-s101
TR201819805T4 (tr) Flavaglin türevleri̇.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
PH12017501668A1 (en) Bace1 inhibitors
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
MX2021014941A (es) Inhibidores de dopamina-b-hidroxilasa.
EA201990763A1 (ru) Ингибиторы дофамин-в-гидроксилазы, проникающие через гематоэнцефалический барьер
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.